Delving into the Latest Updates on Edifoligide sodium with Synapse

Overview

Basic Info

Drug Type

TF Decoy

Synonyms

E2F decoy ODN, E2F duplex decoy, E2F transcription factor decoy

+ [7]

Target

E2F1

Mechanism

E2F1 inhibitors(Transcription factor E2F1 inhibitors)

Therapeutic Areas

Cardiovascular DiseasesOther DiseasesUrogenital Diseases

Active Indication-

Inactive Indication

Arterial Occlusive DiseasesCoronary Artery DiseaseGraft Occlusion, Vascular+ [4]

Originator Organization

Anesiva, Inc.

Active Organization-

Inactive Organization

Anesiva, Inc.

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure

Boost your research with our RNA technology data.

login

or

view full example data

Boost your research with our RNA technology data.

Gene Sequence

Sequence Code 29359050

Source: *****

Sequence Code 29883143

Source: *****

A Phase 1/2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Pilot Trial to Assess the Effect of Treatment of the Recipient Vein of a Polytetrafluoroethylene (PTFE) Vascular Access Graft With Two Concentrations of E2F Decoy as Compared to Placebo on Neointimal Hyperplasia and the Preservation of Graft Function in Patients With Chronic Renal Failure Requiring Hemodialysis

The purpose of this study is to determine the effect of recipient vein pretreatment of edifoligide (E2F Decoy), compared to placebo, on graft/recipient vein stenosis in polytetrafluoroethylene (PTFE) vascular access grafts placed for hemodialysis at 6 months after enrollment.

Start Date01 May 2004

Sponsor / Collaborator

Anesiva, Inc.

NCT00042081 / CompletedPhase 3

A Phase III, Multi-Center Randomized, Double-Blind, Placebo-Controlled Trial of the Ex Vivo Treatment With CGT003 of Coronary Vein Grafts in Patients Undergoing Coronary Artery Bypass Graft Procedures

The purpose of this study is to determine the efficacy of graft pretreatment with CGT003 (E2F Duplex Decoy), as compared to placebo, on the incidence of patients experiencing vein graft failure after coronary artery bypass surgery.

Start Date01 Jul 2002

Sponsor / Collaborator

Anesiva, Inc.

NCT00041925 / CompletedPhase 2/3

A Phase III, Multi-Center Randomized, Double-Blind, Placebo-Controlled Trial of the Ex Vivo Treatment With CGT003 of Peripheral Vein Grafts in Patients Undergoing Peripheral Arterial Bypass Graft Procedures

The purpose of this study is to determine the efficacy of graft pretreatment with the E2F decoy, CGT003, as compared to placebo, on the occurrence of graft failure among patients who receive autogenous vein grafts to treat chronic critical limb ischemia; on the occurrence of clinically significant graft stenosis (more than or equal to 70%); and on the incidence of critical limb ischemia (e.g., gangrene, non-healing ischemic ulcers or ischemic rest pain).

Start Date01 Nov 2001

Sponsor / Collaborator

Anesiva, Inc.

100 Clinical Results associated with Edifoligide sodium

Login to view more data

100 Translational Medicine associated with Edifoligide sodium

Login to view more data

100 Patents (Medical) associated with Edifoligide sodium

Login to view more data

70

Literatures (Medical) associated with Edifoligide sodium

01 Jan 2024·Oncology Research

Combinational therapy with Myc decoy oligodeoxynucleotides encapsulated in nanocarrier and X-irradiation on breast cancer cells

Article

Author: Sharafi, Ali ; Gharbavi, Mahmoud ; Parvinzad Leilan, Milad ; Johari, Behrooz ; Rezaeejam, Hamed ; Mortazavi, Yousef

The Myc gene is the essential oncogene in triple-negative breast cancer (TNBC). This study investigates the synergistic effects of combining Myc decoy oligodeoxynucleotides-encapsulated niosomes-selenium hybrid nanocarriers with X-irradiation exposure on the MDA-MB-468 cell line. Decoy and scramble ODNs for Myc transcription factor were designed and synthesized based on promoter sequences of the Bcl2 gene. The nanocarriers were synthesized by loading Myc ODNs and selenium into chitosan (Chi-Se-DEC), which was then encapsulated in niosome-nanocarriers (NISM@Chi-Se-DEC). FT-IR, DLS, FESEM, and hemolysis tests were applied to confirm its characterization and physicochemical properties. Moreover, cellular uptake, cellular toxicity, apoptosis, cell cycle, and scratch repair assays were performed to evaluate its anticancer effects on cancer cells. All anticancer assessments were repeated under X-ray irradiation conditions (fractionated 2Gy). Physicochemical characteristics of niosomes containing SeNPs and ODNs showed that it is synthesized appropriately. It revealed that the anticancer effect of NISM@Chi-Se-DEC can be significantly improved in combination with X-ray irradiation treatment. It can be concluded that NISM@Chi-Se-DEC nanocarriers have the potential as a therapeutic agent for cancer treatment, particularly in combination with radiation therapy and in-vivo experiments are necessary to confirm the efficacy of this nano-drug.

02 Nov 2022·Cancer Immunology Research

Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand–Expressing Solid Tumors

Article

Author: Bajgain, Pradip ; Balasubramanian, Kishore ; Vera, Juan ; Heslop, Helen E. ; Fleckenstein, Lindsey ; Torres Chavez, Alejandro G. ; Leen, Ann M. ; Lulla, Premal

AbstractT-cell immunotherapy has demonstrated remarkable clinical outcomes in certain hematologic malignancies. However, efficacy in solid tumors has been suboptimal, partially due to the hostile tumor microenvironment composed of immune-inhibitory molecules. One such suppressive agent abundantly expressed in solid tumors is Fas ligand (FasL), which can trigger apoptosis of Fas-expressing effector cells such as T cells and natural killer (NK) cells. To alleviate this FasL-induced suppression of tumor-specific immune cells in solid tumors, we describe here the development of a Fas decoy that is secreted by engineered cells upon activation and sequesters the ligand, preventing it from engaging with Fas on the surface of effector cells. We further improved the immune-stimulatory effects of this approach by creating a Fas decoy and IL15 cytokine fusion protein, which enhanced the persistence and antitumor activity of decoy-engineered as well as bystander chimeric-antigen receptor (CAR) T cells in xenograft models of pancreatic cancer. Our data indicate that secreted Fas decoys can augment the efficacy of both adoptively transferred and endogenous tumor-specific effector cells in FasL-expressing solid tumors.

01 Jan 2021·Redox BiologyQ1 · BIOLOGY

Activation of the mechanosensitive Ca2+ channel TRPV4 induces endothelial barrier permeability via the disruption of mitochondrial bioenergetics

Q1 · BIOLOGY

ArticleOA

Author: Song, Shanshan ; Yuan, Jason X-J ; Lu, Qing ; Wang, Hui ; Zemskov, Evgeny A ; Kangath, Archana ; Black, Stephen M ; Wu, Xiaomin ; Cabanillas, Gabriela Zubiate ; Tang, Haiyang ; Garcia-Flores, Alejandro ; Wang, Ting ; Yegambaram, Manivannan ; Sun, Xutong ; Fineman, Jeffrey R

Mechanical ventilation is a life-saving intervention in critically ill patients with respiratory failure due to acute respiratory distress syndrome (ARDS), a refractory lung disease with an unacceptable high mortality rate. Paradoxically, mechanical ventilation also creates excessive mechanical stress that directly augments lung injury, a syndrome known as ventilator-induced lung injury (VILI). The specific mechanisms involved in VILI-induced pulmonary capillary leakage, a key pathologic feature of VILI are still far from resolved. The mechanoreceptor, transient receptor potential cation channel subfamily V member 4, TRPV4 plays a key role in the development of VILI through unresolved mechanism. Endothelial nitric oxide synthase (eNOS) uncoupling plays an important role in sepsis-mediated ARDS so in this study we investigated whether there is a role for eNOS uncoupling in the barrier disruption associated with TRPV4 activation during VILI. Our data indicate that the TRPV4 agonist, 4α-Phorbol 12,13-didecanoate (4αPDD) induces pulmonary arterial endothelial cell (EC) barrier disruption through the disruption of mitochondrial bioenergetics. Mechanistically, this occurs via the mitochondrial redistribution of uncoupled eNOS secondary to a PKC-dependent phosphorylation of eNOS at Threonine 495 (T495). A specific decoy peptide to prevent T495 phosphorylation reduced eNOS uncoupling and mitochondrial redistribution and preserved PAEC barrier function under 4αPDD challenge. Further, our eNOS decoy peptide was able to preserve lung vascular integrity in a mouse model of VILI. Thus, we have revealed a functional link between TRPV4 activation, PKC-dependent eNOS phosphorylation at T495, and EC barrier permeability. Reducing pT495-eNOS could be a new therapeutic approach for the prevention of VILI.

100 Deals associated with Edifoligide sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03949	-	-	DB06556

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Coronary Artery Disease	Phase 3	US	Anesiva, Inc.	01 Jul 2002
Arterial Occlusive Diseases	Phase 3	CA	Anesiva, Inc.	01 Nov 2001
Graft Occlusion, Vascular	Phase 3	CA	Anesiva, Inc.	01 Nov 2001
Graft Occlusion, Vascular	Phase 3	US	Anesiva, Inc.	01 Nov 2001
Hyperplasia	Phase 3	US	Anesiva, Inc.	01 Nov 2001
Hyperplasia	Phase 3	CA	Anesiva, Inc.	01 Nov 2001
Ischemia	Phase 3	CA	Anesiva, Inc.	01 Nov 2001
Ischemia	Phase 3	US	Anesiva, Inc.	01 Nov 2001
Peripheral Vascular Diseases	Phase 3	US	Anesiva, Inc.	01 Nov 2001
Peripheral Vascular Diseases	Phase 3	CA	Anesiva, Inc.	01 Nov 2001

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00042081 (PREVENT IV, Pubmed \| Am Heart J)	Phase 3	-	-	Edifoligide	(tniuwrvomo) = pokvfakbft rvqqnpixpg (kgrwaozxwe ) View more	-	01 Sep 2012
				Placebo	(tniuwrvomo) = ibxzafiymo rvqqnpixpg (kgrwaozxwe ) View more
NCT00042081 (Prevent IV, Pubmed \| J Coll Physicians Surg Pak)	Phase 3	complication of coronary artery bypass graft	3,014	Edifoligide	rmomrotcax(tyzpvwskfx) = mnicjunoic azglkvlrep (bwgkehaeoj ) View more	Negative	16 Nov 2005
				Placebo	rmomrotcax(tyzpvwskfx) = xmakvaftmv azglkvlrep (bwgkehaeoj ) View more